Investments – Page 5

Workforce reduction (8%), $700 million cost savings, Strategic overhaul, Generics to biopharmaceuticals pivot, Operational streamlining, R&D investment

Gilead tees up $11B in new US manufacturing, R&D investments

6 months ago talkbio0Tagged Billion, Investments, Manufacture, R&D, U.S., United States

United States, Investments, Manufacture, R&D, Billion, U.S.

J&J’s $130M gene therapy bet flunks rare retinal disease trial

6 months ago talkbio0Tagged bota-vec, Disorder of eye, Failure (biologic function), gene therapy, Infrequent, Investments, Johnson and Johnson, loss treatment, Phase 3, Vision, X-linked retinitis pigmentosa

Johnson & Johnson, gene therapy, bota-vec, X-linked retinitis pigmentosa, Phase 3 failure, vision loss treatment, rare eye disease, $130 million investment

Deerfield raises $600M healthcare fund to invest in therapeutics, AI

6 months ago talkbio0Tagged Artificial Intelligence, Deerfield, Drug Development, Health care facility, Investments

Deerfield, Artificial Intelligence, Investments, Drug Development, Health care facility

AstraZeneca’s China woes recede as focus shifts to upcoming readouts

6 months ago talkbio0Tagged Acquisition, Beijing, biotech, China, China legal issues resolution, FibroGen, Fine - adjective, global strategic R&D center, Investments, Manufacturing, partnerships, R&D

$2.5 billion R&D investment in Beijing, Global strategic R&D center, China legal issues resolution, Biotech partnerships, Manufacturing expansion, $8 million potential fine, FibroGen China acquisition

Pfizer CEO Bourla suggests pharma tariffs will focus on US adversaries, not allies

6 months ago talkbio0Tagged Administration occupational activities, Albert, Bourla, chain concerns, Evaluation, Investments, Manufacturing, National Security, pharmaceutical tariffs, Policy, Sectioning technique, TNFRSF19 gene, Transplant Registry Unified Management Program

Pharmaceutical tariffs, Section 232 investigation, Albert Bourla, national security, trade policy, manufacturing investments, Trump administration, supply chain concerns

Biohaven, after setbacks, sees shares jump with Oberland Capital funding agreement worth up to $600M

6 months ago talkbio0Tagged Approved, Ataxia, Spinocerebellar, Capital, Investments, non-dilutive, Note (document), secured, United States Food and Drug Administration

Biohaven, Oberland Capital, $600 million investment, troriluzole, spinocerebellar ataxia (SCA), non-dilutive funding, FDA approval, senior secured notes